Research and Development

Neovii supports research and development activities in the fields of solid organ transplantation, stem cell transplantation, and immune and hemato-oncological disorders.

Neovii actively seeks in-licensing and acquisitions opportunities. We are looking to expand our portfolio of products with novel life-transforming therapies that address severe unmet medical needs in particular in the areas of transplantation, hemato-oncology, and immune disorders.

If you are interested in exploring potential collaborative opportunities with us, please contact us.

Expanded Access Program

Access to Investigational Drugs

The term expanded access is used to describe treatment with an investigational product for a patient with a serious or immediately life-threatening illness when there are no comparable or satisfactory alternative treatments available and the patient is ineligible or unable to participate in a clinical trial.

At the present Neovii does not offer an Expanded Access Program. However, Neovii continues to evaluate implementation of Expanded Access Program and will publish the Expanded Access Policy should it become available in the future.